title: Risk factors for lipodystrophy in the CISAI cohort.
abstract: OBJECTIVE
  This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study.
  
  
  METHODS
  The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports.
  
  
  RESULTS
  The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3).
  
  
  CONCLUSIONS
  The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.
authors.affiliation: I Divisione Malattie Infettive, Ospedale Luigi Sacco, Via GB Grassi 74, 20157, Milan, Italy. paolo.bonfanti@tin.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonfanti
authors.forename: Cecilia
authors.initials: C
authors.lastname: Gulisano
authors.forename: Elena
authors.initials: E
authors.lastname: Ricci
authors.forename: Lia
authors.initials: L
authors.lastname: Timillero
authors.forename: Laura
authors.initials: L
authors.lastname: Valsecchi
authors.forename: Silvia
authors.initials: S
authors.lastname: Carradori
authors.forename: Luigi
authors.initials: L
authors.lastname: Pusterla
authors.forename: Paolo
authors.initials: P
authors.lastname: Fortuna
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Miccolis
authors.forename: Carlo
authors.initials: C
authors.lastname: Magnani
authors.forename: Andrea
authors.initials: A
authors.lastname: Gabbuti
authors.forename: Fabio
authors.initials: F
authors.lastname: Parazzini
authors.forename: Canio
authors.initials: C
authors.lastname: Martinelli
authors.forename: Ivano
authors.initials: I
authors.lastname: Faggion
authors.forename: Simona
authors.initials: S
authors.lastname: Landonio
authors.forename: Tiziana
authors.initials: T
authors.lastname: Quirino
authors.forename: GianMarco
authors.initials: G
authors.lastname: Vigevani
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000367:Age Factors; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D012307:Risk Factors
chemical_list: D017320:HIV Protease Inhibitors